#JPM22: Catal­ent CEO John Chimin­s­ki with John Car­roll — Our pre­dic­tions for the bio­phar­ma in­dus­try in 2022

Dur­ing our JPM22 week of events, I had a chance to sit down with Catal­ent CEO John Chimin­s­ki for our an­nu­al fore­cast for the year ahead. It’s al­ways a lot of fun, and Chimin­s­ki had a chance to talk about the big tran­si­tion ahead for his com­pa­ny, CD­MOs, and what looks like a very event­ful 12 months for bio­phar­ma. — John Car­roll

John Car­roll:

Okay! Well. Hey, every­body. This is John Car­roll, I’m the ed­i­tor of End­points News. And I am very hap­py to in­tro­duce John Chimin­s­ki back again, CEO of Catal­ent. And John is join­ing me once again to be talk­ing about what’s go­ing on next year, what’s hap­pen­ing. We’ve done this be­fore. Gen­er­al­ly, it’s al­ways good to have you be here, John. But one thing that we can say that’s ab­solute­ly cer­tain that’s go­ing to hap­pen in 2022 is there’s go­ing to be a tran­si­tion at Catal­ent. And I want­ed to talk a lit­tle bit about that.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN